Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch

This page shows the latest Deal Watch news and features for those working in and with pharma, biotech and healthcare.

The M&A trend in pharma

The M&A trend in pharma

The lion's share of deal-making in 2014 continued to revolve around Western markets. ... Read more about pharma's M&A activity in the latest Deal Watch article.

Latest news

  • The hunted now hunt: biotechs become buyers The hunted now hunt: biotechs become buyers

    Biotech deals feature in our latest Deal Watch article.

  • Biologics buoyant

    This continues the biologics trend noted in previous Deal Watch reviews. ... One deal of note during this period was the entry of Bayer Healthcare's dermatology business, Intendis, into the aesthetic dermatology area.

  • Orphan drug focus

    During this period, GSK closed its deal with Nabi for NicVax, a nicotine addiction vaccine in phase III (this was announced in the Deal Watch article on page 15 of the ... P2. 960. Cellzome/GSK. inflammatory disease. Platform. 690. Ariad/Merck.

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    When writing this bimonthly edition of Medius’s Deal Watch I have been struck by how often the words 'it’s unusual.' have appeared. ... Novartis. Deal Type. Deal with. Details. Value. Acquisition. Endocyte. Portfolio of products and technology for.

  • Deal Watch January 2018

    and a third undisclosed discovery stage programme.  More details on the financials for the deal are summarised below. ... Teva/Alder Biopharmaceuticals patent settlement. We have featured Teva in Deal Watch over the last few months but focused more on

  • Pharma deals continue to slide Pharma deals continue to slide

    Deal Watch investigates. There is plenty of evidence that the number and value of biopharma M&A and licensing deals in 2016 and 2017 is declining. ... This month Deal Watch reviews the potential impact of some of the macroeconomic factors and the impact

  • Deal Watch - May 2017 Deal Watch - May 2017

    due diligence had identified the issues Abbott had chosen to sign the deal. ... In both cases the upfront is around 44% of the total deal value.

  • Deal Watch March 2017 Deal Watch March 2017

    Each month the Deal Watch team ploughs our merry way through the details of 600 plus deals to bring you the edited highlights. ... X-Chem does it again. Twice. In Japanese. X-Chem is a name that comes up with great regularity in the Deal Watch database.

More from intelligence
Approximately 78 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics